TIFFANEY COLEMAN: Open Payments
NPI 1770096232 · PARIS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,530 in 90 payments from 11 companies in 2025. Trend: 2023 $645 · 2024 $796 · 2025 $1,530
Food & beverage: $1,530
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $319 |
| Axsome Therapeutics, Inc. | 13 | $286 |
| Neurocrine BioSciences, Inc. | 12 | $197 |
| Teva Pharmaceuticals USA, Inc. | 8 | $190 |
| E.R. Squibb & Sons, L.L.C. | 13 | $159 |
| Alkermes, Inc. | 9 | $135 |
| Vanda Pharmaceuticals Inc. | 4 | $86 |
| Otsuka America Pharmaceutical, Inc. | 4 | $77 |
| ABBVIE INC. | 2 | $33 |
| Lundbeck LLC | 2 | $30 |
Products named: CAPLYTA, Auvelity, INGREZZA, UZEDY, COBENFY, ARISTADA, REXULTI, FANAPT.
Industry payments across TX — which companies pay providers there.
